Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- Status
- COMPLETED
- Phase
- PHASE1
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
- Status
- COMPLETED
- Phase
- PHASE1
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- Status
- WITHDRAWN
- Phase
- PHASE3
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2